Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2018, Article ID 5823684, 14 pages
https://doi.org/10.1155/2018/5823684
Review Article

The Pathophysiological Mechanisms and the Quest for Biomarkers in Psoriasis, a Stress-Related Skin Disease

1“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
2Department of Dermatology, “Dr. Victor Babes” Hospital, Bucharest, Romania

Correspondence should be addressed to Maria-Isabela Sarbu; moc.oohay@ubras_alebasi

Received 13 October 2017; Revised 20 December 2017; Accepted 28 December 2017; Published 28 January 2018

Academic Editor: Ana P. Herrmann

Copyright © 2018 Mircea Tampa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Vachatova, C. Andrys, J. Krejsek et al., “Metabolic syndrome and selective inflammatory markers in psoriatic patients,” Journal of Immunology Research, vol. 2016, Article ID 5380792, 8 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Wolff, L. Goldsmith, S. Katz et al., Fitzpatrick’s Dermatology in General Medicine, McGrawHill, New York, 8th edition, 2012.
  3. T. Burns, S. Breathnach, N. Cox, and C. Griffiths, Rook’s Textbook of Dermatology, Wiley Blackwell, Hoboken, NJ, USA, 8th edition, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. J. L. Jorizzo, J. L. Bolognia, and J. V. Schaffer, Dermatology, Elsevier, Amsterdam, Netherlands, 3rd edition, 2012.
  5. R. J. Hay, N. E. Johns, H. C. Williams et al., “The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions,” Journal of Investigative Dermatology, vol. 134, no. 6, pp. 1527–1534, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. F. J. Dalgard, U. Gieler, L. Tomas-Aragones et al., “The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries,” Journal of Investigative Dermatology, vol. 135, no. 4, pp. 984–991, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Pompili, M. Innamorati, A. Forte et al., “Psychiatric comorbidity and suicidal ideation in psoriasis, melanoma and allergic disorders,” International Journal of Psychiatry in Clinical Practice, vol. 21, no. 3, pp. 209–214, 2017. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Pompili, M. Innamorati, S. Trovarelli et al., “Suicide risk and psychiatric comorbidity in patients with psoriasis,” Journal of International Medical Research, vol. 44, Supplement 1, pp. 61–66, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Møller, S. Erntoft, G. Vinding, G. B. Jemec, and N. Karaoghlanian, “A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values,” Patient Related Outcome Measures, vol. 6, pp. 167–177, 2015. View at Publisher · View at Google Scholar
  10. D. G. Fortune, H. L. Richards, and C. E. Griffiths, “Psychologic factors in psoriasis: consequences, mechanisms, and interventions,” Dermatologic Clinics, vol. 23, no. 4, pp. 681–694, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. A. B. Kimball, C. Jacobson, S. Weiss, M. G. Vreeland, and Y. Wu, “The psychosocial burden of psoriasis,” American Journal of Clinical Dermatology, vol. 6, no. 6, pp. 383–392, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. K. H. Basavaraj, M. A. Navya, and R. Rashmi, “Stress and quality of life in psoriasis: an update,” International Journal of Dermatology, vol. 50, no. 7, pp. 783–792, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. W. JJ, R. B. Penfold, P. Primatesta et al., “The risk of depression, suicidal ideation and suicide attempt in patients with psoriasis, psoriatic arthritis or ankylosing spondylitis,” Journal of the European Academy of Dermatology and Venereology, vol. 31, no. 7, pp. 1168–1175, 2017. View at Publisher · View at Google Scholar · View at Scopus
  14. S. K. Kurd, A. B. Troxel, P. Crits-Christoph, and J. M. Gelfand, “The risk of depression, anxiety and suicidality in patients with psoriasis: a population-based cohort study,” Archives of Dermatology, vol. 146, no. 8, pp. 891–895, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. M. I. Sarbu, A. E. Sarbu, and S. R. Georgescu, “Sexual dysfunctions in psoriatic patients,” Journal of Mind and Medical Sciences, vol. 1, no. 1, pp. 19–27, 2014. View at Google Scholar
  16. B. I. Ferreira, J. L. Abreu, J. P. Reis, and A. M. Figueiredo, “Psoriasis and associated psychiatric disorders: a systematic review on etiopathogenesis and clinical correlation,” The Journal of Clinical and Aesthetic Dermatology, vol. 9, no. 6, pp. 36–43, 2016. View at Google Scholar
  17. M. A. Gupta, N. J. Schork, A. K. Gupta, S. Kirkby, and C. N. Ellis, “Suicidal ideation in psoriasis,” International Journal of Dermatology, vol. 32, no. 3, pp. 188–190, 1993. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Singh, C. Taylor, H. Kornmehl, and A. W. Armstrong, “Psoriasis and suicidality: a systematic review and meta-analysis,” Journal of the American Academy of Dermatology, vol. 77, no. 3, pp. 425–440.e2, 2017. View at Publisher · View at Google Scholar
  19. A. Egeberg, P. R. Hansen, G. H. Gislason, L. Skov, and L. Mallbris, “Risk of self-harm and nonfatal suicide attempts, and completed suicide in patients with psoriasis: a population-based cohort study,” British Journal of Dermatology, vol. 175, no. 3, pp. 493–500, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. D. G. Fortune, C. J. Main, T. M. O'Sullivan, and C. E. Griffiths, “Assessing illness-related stress in psoriasis: the psychometric properties of the Psoriasis Life Stress Inventory,” Journal of Psychosomatic Research, vol. 42, no. 5, pp. 467–475, 1997. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Moynihan, E. Rieder, and F. Tausk, “Psychoneuroimmunology: the example of psoriasis,” Giornale Italiano di Dermatologia e Venereologia, vol. 145, no. 2, pp. 221–228, 2010. View at Google Scholar
  22. A. Steptoe, M. Hamer, and Y. Chida, “The effects of acute psychological stress on circulating inflammatory factors in humans: a review and meta-analysis,” Brain, Behavior, and Immunity, vol. 21, no. 7, pp. 901–912, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Maes, C. Song, A. Lin et al., “The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and Th1-like response in stress-induced anxiety,” Cytokine, vol. 10, no. 4, pp. 313–318, 1998. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Reichenberg, R. Yirmiya, A. Schuld et al., “Cytokine-associated emotional and cognitive disturbances in humans,” Archives of General Psychiatry, vol. 58, no. 5, pp. 445–452, 2001. View at Publisher · View at Google Scholar
  25. S. Tyring, A. Gottlieb, K. Papp et al., “Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial,” The Lancet, vol. 367, no. 9504, pp. 29–35, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. A. H. Miller, V. Maletic, and C. L. Raison, “Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression,” Biological Psychiatry, vol. 65, no. 9, pp. 732–741, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. C. L. Raison, L. Capuron, and A. H. Miller, “Cytokines sing the blues: inflammation and the pathogenesis of depression,” Trends in Immunology, vol. 27, no. 1, pp. 24–31, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Y. Finlay and G. K. Khan, “Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use,” Clinical and Experimental Dermatology, vol. 19, no. 3, pp. 210–216, 1994. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Sarkar, S. Chugh, and S. Bansal, “General measures and quality of life issues in psoriasis,” Indian Dermatology Online Journal, vol. 7, no. 6, pp. 481–488, 2016. View at Publisher · View at Google Scholar
  30. M. A. Gupta and A. K. Gupta, “The Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stress,” Acta Derm Venereol, vol. 75, no. 3, pp. 240–243, 1995. View at Google Scholar
  31. V. J. Lewis and A. Y. Finlay, “Two decades experience of the Psoriasis Disability Index,” Dermatology, vol. 210, no. 4, pp. 261–268, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. S. P. McKenna, S. A. Cook, D. Whalley et al., “Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials,” British Journal of Dermatology, vol. 149, no. 2, pp. 323–331, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. M. J. Bhosle, A. Kulkarni, S. R. Feldman, and R. Balkrishnan, “Quality of life in patients with psoriasis,” Health and Quality of Life Outcomes, vol. 4, no. 1, p. 35, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. R. G. Langley and C. N. Ellis, “Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician’s global assessment,” Journal of the American Academy of Dermatology, vol. 51, no. 4, pp. 563–569, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Molteni and E. Reali, “Biomarkers in the pathogenesis, diagnosis, and treatment of psoriasis,” Psoriasis: Targets and Therapy, vol. 2, pp. 55–66, 2012. View at Publisher · View at Google Scholar
  36. W. A. Colburn, V. G. DeGruttola, D. L. DeMets et al., “Biomarkers and surrogate endpoints: preferred definitions and conceptual framework,” Clinical Pharmacology & Therapeutics, vol. 69, no. 3, pp. 89–95, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Ryan, J. Kelleher, M. F. Fagan et al., “Genetic markers of treatment response to tumour necrosis factor-α inhibitors in the treatment of psoriasis,” Clinical and Experimental Dermatology, vol. 39, no. 4, pp. 519–524, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. R. Rashmi, K. S. Rao, and K. H. Basavaraj, “A comprehensive review of biomarkers in psoriasis,” Clinical and Experimental Dermatology, vol. 34, no. 6, pp. 658–663, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. P. Mudigonda, T. Mudigonda, A. N. Feneran, H. S. Alamdari, L. Sandoval, and S. R. Feldman, “Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis,” Dermatology Online Journal, vol. 18, no. 10, p. 1, 2012. View at Google Scholar
  40. L. A. Zenewicz and R. A. Flavell, “Recent advances in IL-22 biology,” International Immunology, vol. 23, no. 3, pp. 159–163, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. J. W. Larrick, V. Morhenn, Y. L. Chiang, and T. Shi, “Activated Langerhans cells release tumor necrosis factor,” Journal of Leukocyte Biology, vol. 45, no. 5, pp. 429–433, 1989. View at Publisher · View at Google Scholar
  42. A. J. Schottelius, L. L. Moldawer, C. A. Dinarello, K. Asadullah, W. Sterry, and C. K. Edwards 3rd, “Biology of tumor necrosis factor-α– implications for psoriasis,” Experimental Dermatology, vol. 13, no. 4, pp. 193–222, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. E. Fitch, E. Harper, I. Skorcheva, S. E. Kurtz, and A. Blauvelt, “Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines,” Current Rheumatology Reports, vol. 9, no. 6, pp. 461–467, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. O. FitzGerald and R. Winchester, “Psoriatic arthritis: from pathogenesis to therapy,” Arthritis Research & Therapy, vol. 11, no. 1, p. 214, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Buske-Kirschbaum, S. Kern, M. Ebrecht, and D. H. Hellhammer, “Altered distribution of leukocyte subsets and cytokine production in response to acute psychosocial stress in patients with psoriasis vulgaris,” Brain, Behavior, and Immunity, vol. 21, no. 1, pp. 92–99, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. J. M. Hall, A. Podawiltz, D. I. Mummert, H. Jones, and M. E. Mummert, “Psychological stress and the cutaneous immune response: roles of the HPA axis and the sympathetic nervous system in atopic dermatitis and psoriasis,” Dermatology Research and Practice, vol. 2012, Article ID 403908, 11 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. I. T. Harvima, H. Viinamäki, A. Naukkarinen et al., “Association of cutaneous mast cells and sensory nerves with psychic stress in psoriasis,” Psychotherapy and Psychosomatics, vol. 60, no. 3–4, pp. 168–176, 1993. View at Publisher · View at Google Scholar · View at Scopus
  48. A. W. Evers, E. W. Verhoeven, F. W. Kraaimaat et al., “How stress gets under the skin: cortisol and stress reactivity in psoriasis,” British Journal of Dermatology, vol. 163, no. 5, pp. 986–991, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. C. J. Connor, V. Liu, and J. G. Fiedorowicz, “Exploring the physiological link between psoriasis and mood disorders,” Dermatology Research and Practice, vol. 2015, Article ID 409637, 11 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  50. B. Ç. Cemil, F. Canpolat, D. Yılmazer, F. Eskioğlu, and M. Alper, “The association of PASI scores with CRH-R1 expression in patients with psoriasis,” Archives of Dermatological Research, vol. 304, no. 2, pp. 127–132, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Vasiadi, A. Therianou, K. D. Alysandratos et al., “Serum neurotensin (NT) is increased in psoriasis and NT induces vascular endothelial growth factor release from human mast cells,” British Journal of Dermatology, vol. 166, no. 6, pp. 1349–1352, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. P. Rocha-Pereira, A. Santos-Silva, I. Rebelo, A. Figueiredo, A. Quintanilha, and F. Teixeira, “The inflammatory response in mild and in severe psoriasis,” British Journal of Dermatology, vol. 150, no. 5, pp. 917–928, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Coimbra, H. Oliveira, F. Reis et al., “C-Reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy,” Journal of the European Academy of Dermatology and Venereology, vol. 24, no. 7, pp. 789–796, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. T. Gegenava, M. Gegenava, and G. Kavtaradze, “C-Reactive protein level correlation with depression and anxiety among patients with coronary artery disease,” Georgian Medical News, vol. 194, pp. 34–37, 2011. View at Google Scholar
  55. M. K. Wium-Andersen, D. D. Ørsted, S. F. Nielsen, and B. G. Nordestgaard, “Elevated C-reactive protein levels, psychological distress, and depression in 73 131 individuals,” JAMA Psychiatry, vol. 70, no. 2, pp. 176–184, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. M. S. Cepeda, P. Stang, and R. Makadia, “Depression is associated with high levels of C-reactive protein and low levels of fractional exhaled nitric oxide: results from the 2007-2012 National Health and Nutrition Examination Surveys,” The Journal of Clinical Psychiatry, vol. 77, no. 12, pp. 1666–1671, 2016. View at Publisher · View at Google Scholar · View at Scopus
  57. J. A. Koedam, E. M. Cramer, E. Briend, B. Furie, B. C. Furie, and D. D. Wagner, “P-Selectin, a granule membrane protein of platelets and endothelial cells, follows the regulated secretory pathway in AtT-20 cells,” The Journal of Cell Biology, vol. 116, no. 3, pp. 617–625, 1992. View at Publisher · View at Google Scholar
  58. J. Garbaraviciene, S. Diehl, D. Varwig et al., “Platelet P-selectin reflects a state of cutaneous inflammation: possible application to monitor treatment efficacy in psoriasis,” Experimental Dermatology, vol. 19, no. 8, pp. 736–741, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. K. Aschbacher, P. J. Mills, R. von Känel et al., “Effects of depressive and anxious symptoms on norepinephrine and platelet P-selectin responses to acute psychological stress among elderly caregivers,” Brain, Behavior, and Immunity, vol. 22, no. 4, pp. 493–502, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. M. E. Marina, I. I. Roman, A. M. Constantin, C. M. Mihu, and A. D. Tătaru, “VEGF involvement in psoriasis,” Clujul Medical, vol. 88, no. 3, pp. 247–252, 2015. View at Publisher · View at Google Scholar
  61. M. Canavese, F. Altruda, T. Ruzicka, and J. Schauber, “Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis—a possible target for novel therapies?” Journal of Dermatological Science, vol. 58, no. 3, pp. 171–176, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. M. Bhushan, B. McLaughlin, J. B. Weiss, and C. E. M. Griffiths, “Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis,” British Journal of Dermatology, vol. 141, no. 6, pp. 1054–1060, 1999. View at Publisher · View at Google Scholar · View at Scopus
  63. I. Flisiak, P. Zaniewski, M. Rogalska-Taranta, and B. Chodynicka, “Effect of psoriasis therapy on VEGF and its soluble receptors serum concentrations,” Journal of the European Academy of Dermatology and Venereology, vol. 26, no. 3, pp. 302–307, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. H. Q. Chen, X. Li, and R. Tang, “Effects of narrow band ultraviolet B on serum levels of vascular endothelial growth factor and interleukin-8 in patients with psoriasis,” American Journal of Therapeutics, vol. 23, no. 3, pp. e655–e662, 2016. View at Publisher · View at Google Scholar · View at Scopus
  65. A. Akman, E. Yilmaz, H. Mutlu, and M. Ozdogan, “Complete remission of psoriasis following bevacizumab therapy for colon cancer,” Clinical and Experimental Dermatology, vol. 34, no. 5, pp. e202–e204, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. H. B. Schonthaler, R. Huggenberger, S. K. Wculek, M. Detmar, and E. F. Wagner, “Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 50, pp. 21264–21269, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Nowacka and E. Obuchowicz, “BDNF and VEGF in the pathogenesis of stress-induced affective diseases: an insight from experimental studies,” Pharmacological Reports, vol. 65, no. 3, pp. 535–546, 2013. View at Publisher · View at Google Scholar
  68. G. Han, C. A. Williams, K. Salter, P. J. Garl, A. G. Li, and X. J. Wang, “A role for TGFβ signaling in the pathogenesis of psoriasis,” Journal of Investigative Dermatology, vol. 130, no. 2, pp. 371–377, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. I. Flisiak, B. Chodynicka, P. Porebski, and R. Flisiak, “Association between psoriasis severity and transforming growth factor β1 and β2 in plasma and scales from psoriatic lesions,” Cytokine, vol. 19, no. 3, pp. 121–125, 2002. View at Publisher · View at Google Scholar · View at Scopus
  70. I. Flisiak, P. Porębski, R. Flisiak, and B. Chodynicka, “Plasma transforming growth factor β1 as a biomarker of psoriasis activity and treatment efficacy,” Biomarkers, vol. 8, no. 5, pp. 437–443, 2003. View at Publisher · View at Google Scholar · View at Scopus
  71. H. Zaher, O. G. Shaker, M. H. EL-Komy, A. El-Tawdi, M. Fawzi, and D. Kadry, “Serum and tissue expression of transforming growth factor beta 1 in psoriasis,” Journal of the European Academy of Dermatology and Venereology, vol. 23, no. 4, pp. 406–409, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. A. R. Meki and H. Al-Shobaili, “Serum vascular endothelial growth factor, transforming growth factor β1, and nitric oxide levels in patients with psoriasis vulgaris: their correlation to disease severity,” Journal of Clinical Laboratory Analysis, vol. 28, no. 6, pp. 496–501, 2014. View at Publisher · View at Google Scholar · View at Scopus
  73. I. Flisiak, P. Zaniewski, and B. Chodynicka, “Plasma TGF-β1, TIMP-1, MMP-1 and IL-18 as a combined biomarker of psoriasis activity,” Biomarkers, vol. 13, no. 5, pp. 549–556, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. Z. You, C. Luo, W. Zhang et al., “Pro- and anti-inflammatory cytokines expression in rat’s brain and spleen exposed to chronic mild stress: involvement in depression,” Behavioural Brain Research, vol. 225, no. 1, pp. 135–141, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. S. Morizane and R. L. Gallo, “Antimicrobial peptides in the pathogenesis of psoriasis,” The Journal of Dermatology, vol. 39, no. 3, pp. 225–230, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. L. Dongsheng, L. Jiawen, D. Yiqun, and Z. Xiaoyong, “Expression of LL-37, human beta defensin-2, and CCR6 mRNA in patients with psoriasis vulgaris,” Journal of Huazhong University of Science and Technology [Medical Sciences], vol. 24, no. 4, pp. 404–406, 2004. View at Publisher · View at Google Scholar
  77. E. J. Hollox, U. Huffmeier, P. L. Zeeuwen et al., “Psoriasis is associated with increased β-defensin genomic copy number,” Nature Genetics, vol. 40, no. 1, pp. 23–25, 2008. View at Publisher · View at Google Scholar · View at Scopus
  78. P. A. Jansen, D. Rodijk-Olthuis, E. J. Hollox et al., “β-Defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin,” PLoS One, vol. 4, no. 3, article e4725, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. T. Jin, Z. Sun, X. Chen et al., “Serum human beta-defensin-2 is a possible biomarker for monitoring response to JAK inhibitor in psoriasis patients,” Dermatology, vol. 233, no. 2–3, pp. 164–169, 2017. View at Publisher · View at Google Scholar
  80. F. Kolbinger, C. Loesche, M. A. Valentin et al., “β-Defensin 2 is a responsive biomarker of IL-17A–driven skin pathology in patients with psoriasis,” The Journal of Allergy and Clinical Immunology, vol. 139, no. 3, pp. 923–932.e8, 2017. View at Publisher · View at Google Scholar · View at Scopus
  81. H. SC, Y. HS, F. L. Yen, C. L. Lin, G. S. Chen, and C. C. Lan, “Neutrophil extracellular trap formation is increased in psoriasis and induces human β-defensin-2 production in epidermal keratinocytes,” Scientific Reports, vol. 6, no. 1, article 31119, 2016. View at Publisher · View at Google Scholar · View at Scopus
  82. K. M. Aberg, K. A. Radek, E. H. Choi et al., “Psychological stress downregulates epidermal antimicrobial peptide expression and increases severity of cutaneous infections in mice,” The Journal of Clinical Investigation, vol. 117, no. 11, pp. 3339–3349, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. G. Martin-Ezquerra, M. A. Mao-Qiang, H. U. Melanie et al., “Psychological stress regulates antimicrobial peptide expression by both glucocorticoid and β-adrenergic mechanisms,” European Journal of Dermatology, vol. 21, Supplement 2, pp. 48–51, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. S. Benoit, A. Toksoy, M. Ahlmann et al., “Elevated serum levels of calcium-binding S100 proteins A8 and A9 reflect disease activity and abnormal differentiation of keratinocytes in psoriasis,” British Journal of Dermatology, vol. 155, no. 1, pp. 62–66, 2006. View at Publisher · View at Google Scholar · View at Scopus
  85. K. S. Anderson, J. Wong, K. Polyak, D. Aronzon, and C. Enerbäck, “Detection of psoriasin/S100A7 in the sera of patients with psoriasis,” British Journal of Dermatology, vol. 160, no. 2, pp. 325–332, 2009. View at Publisher · View at Google Scholar · View at Scopus
  86. D. Wilsmann-Theis, J. Wagenpfeil, D. Holzinger et al., “Among the S100 proteins, S100A12 is the most significant marker for psoriasis disease activity,” Journal of the European Academy of Dermatology and Venereology, vol. 30, no. 7, pp. 1165–1170, 2016. View at Publisher · View at Google Scholar · View at Scopus
  87. O. Arican, M. Aral, S. Sasmaz, and P. Ciragil, “Serum levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity,” Mediators of Inflammation, vol. 2005, no. 5, pp. 273–279, 2005. View at Publisher · View at Google Scholar · View at Scopus
  88. A. Pietrzak, B. Lecewicz-Torun, G. Chodorowska, and J. Rolinski, “Interleukin-18 levels in the plasma of psoriatic patients correlate with the extent of skin lesions and the PASI score,” Acta Dermato-Venereologica, vol. 83, no. 4, pp. 262-263, 2003. View at Publisher · View at Google Scholar · View at Scopus
  89. I. Flisiak, A. Klepacki, and B. Chodynicka, “Plasma and scales levels of interleukin 18 in comparison with other possible clinical and laboratory biomarkers of psoriasis activity,” Biomarkers, vol. 11, no. 2, pp. 194–200, 2006. View at Publisher · View at Google Scholar · View at Scopus
  90. M. Mastrolonardo, D. Alicino, R. Zefferino, P. Pasquini, and A. Picardi, “Effect of psychological stress on salivary interleukin-1β in psoriasis,” Archives of Medical Research, vol. 38, no. 2, pp. 206–211, 2007. View at Publisher · View at Google Scholar · View at Scopus
  91. C. Hirotsu, M. Rydlewski, M. S. Araujo, S. Tufik, and M. L. Andersen, “Sleep loss and cytokines levels in an experimental model of psoriasis,” PLoS One, vol. 7, no. 11, article e51183, 2012. View at Publisher · View at Google Scholar · View at Scopus
  92. C. Schick, Y. Kamachi, A. J. Bartuski et al., “Squamous cell carcinoma antigen 2 is a novel serpin that inhibits the chymotrypsin-like proteinases cathepsin G and mast cell chymase,” Journal of Biological Chemistry, vol. 272, no. 3, pp. 1849–1855, 1997. View at Publisher · View at Google Scholar · View at Scopus
  93. M. Chechlinska, M. Kowalewska, E. Brzoska-Wojtowicz et al., “Squamous cell carcinoma antigen 1 and 2 expression in cultured normal peripheral blood mononuclear cells and in vulvar squamous cell carcinoma,” Tumor Biology, vol. 31, no. 6, pp. 559–567, 2010. View at Publisher · View at Google Scholar · View at Scopus
  94. E. S. Piruzian, V. V. Sobolev, R. M. Abdeev et al., “Study of molecular mechanisms involved in the pathogenesis of immune-mediated inflammatory diseases, using psoriasis as a model,” Acta Naturae, vol. 1, no. 3, 2009. View at Google Scholar
  95. Y. Watanabe, Y. Yamaguchi, N. Komitsu et al., “Elevation of serum squamous cell carcinoma antigen 2 in patients with psoriasis: associations with disease severity and response to the treatment,” British Journal of Dermatology, vol. 174, no. 6, pp. 1327–1336, 2016. View at Publisher · View at Google Scholar · View at Scopus
  96. T. Sano, T. Kume, T. Fujimura et al., “Long-term alteration in the expression of keratins 6 and 16 in the epidermis of mice after chronic UVB exposure,” Archives of Dermatological Research, vol. 301, no. 3, pp. 227–237, 2009. View at Publisher · View at Google Scholar · View at Scopus
  97. M. Komine, L. S. Rao, I. M. Freedberg, M. Simon, V. Milisavljevic, and M. Blumenberg, “Interleukin-1 induces transcription of keratin K6 in human epidermal keratinocytes,” Journal of Investigative Dermatology, vol. 116, no. 2, pp. 330–338, 2001. View at Publisher · View at Google Scholar · View at Scopus
  98. J. M. Mommers, M. M. Van Rossum, P. E. Van Erp, and P. C. Van De Kerkhof, “Changes in keratin 6 and keratin 10 (co-) expression in lesional and symptomless skin of spreading psoriasis,” Dermatology, vol. 201, no. 1, pp. 15–20, 2000. View at Publisher · View at Google Scholar
  99. S. Jiang, T. E. Hinchliffe, and T. Wu, “Biomarkers of an autoimmune skin disease—psoriasis,” Genomics, Proteomics & Bioinformatics, vol. 13, no. 4, pp. 224–233, 2015. View at Publisher · View at Google Scholar · View at Scopus
  100. J. Bhawan, C. Bansal, K. Whren, and U. Schwertschlag, “K16 expression in uninvolved psoriatic skin: a possible marker of pre-clinical psoriasis,” Journal of Cutaneous Pathology, vol. 31, no. 7, pp. 471–476, 2004. View at Publisher · View at Google Scholar · View at Scopus
  101. M. E. Franssen, J. B. Boezeman, P. C. van de Kerkhof, and P. E. van Erp, “Monitoring hyperproliferative disorders in human skin: flow cytometry of changing cytokeratin expression,” Cytometry Part B: Clinical Cytometry, vol. 57B, no. 1, pp. 32–39, 2004. View at Publisher · View at Google Scholar
  102. G. Lemaitre, V. Sivan, J. Lamartine et al., “Connexin 30, a new marker of hyperproliferative epidermis,” British Journal of Dermatology, vol. 155, no. 4, pp. 844–846, 2006. View at Publisher · View at Google Scholar · View at Scopus
  103. T. Lucke, R. Choudhry, R. Thom, I. S. Selmer, A. D. Burden, and M. B. Hodgins, “Upregulation of connexin 26 is a feature of keratinocyte differentiation in hyperproliferative epidermis, vaginal epithelium, and buccal epithelium,” Journal of Investigative Dermatology, vol. 112, no. 3, pp. 354–361, 1999. View at Publisher · View at Google Scholar · View at Scopus
  104. M. Koçak, Ö. Bozdoǧan, E. Erkek, P. Atasoy, and A. Birol, “Examination of Bcl-2, Bcl-X and bax protein expression in psoriasis,” International Journal of Dermatology, vol. 42, no. 10, pp. 789–793, 2003. View at Publisher · View at Google Scholar · View at Scopus
  105. H. M. Beere, “‘The stress of dying’: the role of heat shock proteins in the regulation of apoptosis,” Journal of Cell Science, vol. 117, no. 13, pp. 2641–2651, 2004. View at Publisher · View at Google Scholar · View at Scopus
  106. M. Kakeda, M. Arock, C. Schlapbach, and N. Yawalkar, “Increased expression of heat shock protein 90 in keratinocytes and mast cells in patients with psoriasis,” Journal of the American Academy of Dermatology, vol. 70, no. 4, pp. 683–690.e1, 2014. View at Publisher · View at Google Scholar · View at Scopus
  107. W. Baran, J. C. Szepietowski, and G. Szybejko-Machaj, “Expression of p53 protein in psoriasis,” Acta Dermatovenerologica Alpina Panonica et Adriatica, vol. 14, no. 3, p. 79, 2005. View at Google Scholar
  108. A. G. Abdou, A. H. Maraee, M. Eltahmoudy, and R. A. El-Aziz, “Immunohistochemical expression of GLUT-1 and Ki-67 in chronic plaque psoriasis,” The American Journal of Dermatopathology, vol. 35, no. 7, pp. 731–737, 2013. View at Publisher · View at Google Scholar · View at Scopus
  109. D. O. Jesionek-Kupnicka, D. O. Chomiczewska-Skóra, and H. E. Rotsztejn, “Influence of phototherapy in psoriasis on Ki-67 antigen expression: a preliminary study,” Polish Journal of Pathology, vol. 2, no. 2, pp. 96–103, 2013. View at Publisher · View at Google Scholar · View at Scopus
  110. S. Emre, A. Metin, D. D. Demirseren, S. Kilic, S. Isikoglu, and O. Erel, “The relationship between oxidative stress, smoking and the clinical severity of psoriasis,” Journal of the European Academy of Dermatology and Venereology, vol. 27, no. 3, pp. e370–e375, 2013. View at Publisher · View at Google Scholar · View at Scopus
  111. Q. Zhou, U. Mrowietz, and M. Rostami-Yazdi, “Oxidative stress in the pathogenesis of psoriasis,” Free Radical Biology & Medicine, vol. 47, no. 7, pp. 891–905, 2009. View at Publisher · View at Google Scholar · View at Scopus
  112. I. Peluso, A. Cavaliere, and M. Palmery, “Plasma total antioxidant capacity and peroxidation biomarkers in psoriasis,” Journal of Biomedical Science, vol. 23, no. 1, p. 52, 2016. View at Publisher · View at Google Scholar · View at Scopus
  113. T. Bacchetti, A. Campanati, G. Ferretti, O. Simonetti, G. Liberati, and A. M. Offidani, “Oxidative stress and psoriasis: the effect of antitumour necrosis factor-α inhibitor treatment,” British Journal of Dermatology, vol. 168, no. 5, pp. 984–989, 2013. View at Publisher · View at Google Scholar · View at Scopus
  114. N. Houshang, K. Reza, S. Masoud, E. Ali, R. Mansour, and A. Vaisi-Raygani, “Antioxidant status in patients with psoriasis,” Cell Biochemistry & Function, vol. 32, no. 3, pp. 268–273, 2014. View at Publisher · View at Google Scholar · View at Scopus
  115. A. Şikar Aktürk, H. K. Özdoğan, D. Bayramgürler, M. B. Çekmen, N. Bilen, and R. Kıran, “Nitric oxide and malondialdehyde levels in plasma and tissue of psoriasis patients,” Journal of the European Academy of Dermatology and Venereology, vol. 26, no. 7, pp. 833–837, 2012. View at Publisher · View at Google Scholar · View at Scopus
  116. S. Gerdes, S. Osadtschy, N. Buhles, H. Baurecht, and U. Mrowietz, “Cardiovascular biomarkers in patients with psoriasis,” Experimental Dermatology, vol. 23, no. 5, pp. 322–325, 2014. View at Publisher · View at Google Scholar · View at Scopus
  117. K. Nakai, K. Yoneda, R. Maeda et al., “Urinary biomarker of oxidative stress in patients with psoriasis vulgaris and atopic dermatitis,” Journal of the European Academy of Dermatology and Venereology, vol. 23, no. 12, pp. 1405–1408, 2009. View at Publisher · View at Google Scholar · View at Scopus
  118. L. U. Dinu, C. D. Ene, I. L. Nicolae, M. Tampa, C. Matei, and S. R. Georgescu, “The serum levels of 8-hidroxy-deoxyguanosine under the chemicals influence,” Revista de Chimie, vol. 65, no. 11, pp. 1319–1326, 2014. View at Google Scholar
  119. M. Tampa, I. L. Nicolae, C. D. Ene, I. Sarbu, C. Matei, and S. R. Georgescu, “Vitamin C and thiobarbituric acid reactive substances (TBARS) in psoriasis vulgaris related to psoriasis area severity index (PASI),” Revista de Chimie, vol. 68, no. 1, pp. 43–47, 2017. View at Google Scholar
  120. M. H. Allen, H. Ameen, C. Veal et al., “The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasis,” Journal of Investigative Dermatology, vol. 124, no. 1, pp. 103–106, 2005. View at Publisher · View at Google Scholar · View at Scopus
  121. L. C. Tsoi, S. L. Spain, J. Knight et al., “Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity,” Nature Genetics, vol. 44, no. 12, pp. 1341–1348, 2012. View at Publisher · View at Google Scholar · View at Scopus
  122. F. Capon, P. Di Meglio, J. Szaub et al., “Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis,” Human Genetics, vol. 122, no. 2, pp. 201–206, 2007. View at Publisher · View at Google Scholar · View at Scopus
  123. U. Hüffmeier, S. Uebe, A. B. Ekici et al., “Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis,” Nature Genetics, vol. 42, no. 11, pp. 996–999, 2010. View at Publisher · View at Google Scholar · View at Scopus
  124. S. Kagami, H. L. Rizzo, J. J. Lee, Y. Koguchi, and A. Blauvelt, “Circulating Th17, Th22, and Th1 cells are increased in psoriasis,” Journal of Investigative Dermatology, vol. 130, no. 5, pp. 1373–1383, 2010. View at Publisher · View at Google Scholar · View at Scopus
  125. H. L. Richards, D. W. Ray, B. Kirby et al., “Response of the hypothalamic–pituitary–adrenal axis to psychological stress in patients with psoriasis,” British Journal of Dermatology, vol. 153, no. 6, pp. 1114–1120, 2005. View at Publisher · View at Google Scholar · View at Scopus
  126. S. J. Brouwer, H. V. Middendorp, C. Stormink et al., “The psychophysiological stress response in psoriasis and rheumatoid arthritis,” British Journal of Dermatology, vol. 170, no. 4, pp. 824–831, 2014. View at Publisher · View at Google Scholar · View at Scopus
  127. V. Chandran, R. J. Cook, J. Edwin et al., “Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis,” Rheumatology, vol. 49, no. 7, pp. 1399–1405, 2010. View at Publisher · View at Google Scholar · View at Scopus
  128. C. Hansson, C. Eriksson, and G. M. Alenius, “S-Calprotectin (S100A8/S100A9): a potential marker of inflammation in patients with psoriatic arthritis,” Journal of Immunology Research, vol. 2014, Article ID 696415, 5 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  129. O. Elkayam, I. Yaron, I. Shirazi, M. Yaron, and D. Caspi, “Serum levels of IL-10, IL-6, IL-1ra, and sIL-2R in patients with psoriatic arthritis,” Rheumatology International, vol. 19, no. 3, pp. 101–105, 2000. View at Publisher · View at Google Scholar
  130. G. M. Alenius, C. Eriksson, and S. Rantapää Dahlqvist, “Interleukin-6 and soluble interleukin-2 receptor alpha – markers of inflammation in patients with psoriatic arthritis?” Clinical and Experimental Rheumatology, vol. 27, no. 1, pp. 120–123, 2009. View at Google Scholar
  131. R. Queiro, I. Morante, I. Cabezas, and B. Acasuso, “HLA-B27 and psoriatic disease: a modern view of an old relationship,” Rheumatology, vol. 55, no. 2, pp. 221–229, 2016. View at Publisher · View at Google Scholar · View at Scopus
  132. D. D. Gladman, V. T. Farewell, K. A. Kopciuk, and R. J. Cook, “HLA markers and progression in psoriatic arthritis,” The Journal of Rheumatology, vol. 25, no. 4, pp. 730–733, 1998. View at Google Scholar